Northern Trust
AVIR icon

Northern Trust’s Atea Pharmaceuticals AVIR Stock Holding History

Northern Trust’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Buy
755,239
+170,214
+29% +$847K ﹤0.01% 2832
2026
Q1 		$3.15M Buy
585,025
+24,807
+4% +$114K ﹤0.01% 2714
2025
Q4 		$2M Sell
560,218
-78,170
-12% -$248K ﹤0.01% 2998
2025
Q3 		$1.85M Sell
638,388
-37,071
-5% -$127K ﹤0.01% 3075
2025
Q2 		$2.43M Sell
675,459
-14,716
-2% -$43.9K ﹤0.01% 2873
2025
Q1 		$2.06M Sell
690,175
-14,734
-2% -$46K ﹤0.01% 2911
2024
Q4 		$2.36M Buy
704,909
+17,471
+3% +$58.1K ﹤0.01% 2930
2024
Q3 		$2.3M Buy
687,438
+26,154
+4% +$94.8K ﹤0.01% 2918
2024
Q2 		$2.19M Sell
661,284
-25,985
-4% -$96.9K ﹤0.01% 2859
2024
Q1 		$2.78M Sell
687,269
-24,244
-3% -$94.9K ﹤0.01% 2794
2023
Q4 		$2.17M Buy
711,513
+45,361
+7% +$137K ﹤0.01% 2958
2023
Q3 		$2M Buy
666,152
+19,409
+3% +$66K ﹤0.01% 2940
2023
Q2 		$2.42M Sell
646,743
-58,301
-8% -$218K ﹤0.01% 2903
2023
Q1 		$2.36M Sell
705,044
-5,894
-0.8% -$23.9K ﹤0.01% 2866
2022
Q4 		$3.42M Sell
710,938
-14,288
-2% -$72.3K ﹤0.01% 2700
2022
Q3 		$4.13M Buy
725,226
+32,100
+5% +$246K ﹤0.01% 2614
2022
Q2 		$4.92M Buy
693,126
+133,106
+24% +$909K ﹤0.01% 2520
2022
Q1 		$4.04M Sell
560,020
-15,248
-3% -$104K ﹤0.01% 2712
2021
Q4 		$5.14M Sell
575,268
-16,093
-3% -$251K ﹤0.01% 2665
2021
Q3 		$20.7M Buy
591,361
+70,939
+14% +$1.97M ﹤0.01% 1782
2021
Q2 		$11.2M Buy
520,422
+353,262
+211% +$10.6M ﹤0.01% 2293
2021
Q1 		$10.3M Sell
167,160
-9,745
-6% -$658K ﹤0.01% 2269
2020
Q4 		$7.39M Buy
+176,905
New +$5.7M ﹤0.01% 2445

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Northern Trust's AVIR Position: Q2 2026 in Review

Northern Trust increased its Atea Pharmaceuticals (AVIR) stake by 29% in Q2 2026, buying an estimated $847K and bringing the position to 755,239 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2832.

Northern Trust first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $20.7M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Northern Trust held 755,239 shares of Atea Pharmaceuticals worth $3.51M as of Q2 2026.
  • Northern Trust bought 170,214 Atea Pharmaceuticals shares in Q2 2026, an estimated $847K.
  • Atea Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2832 holding.
  • Northern Trust first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Northern Trust's Atea Pharmaceuticals position peaked at $20.7M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.